Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2395  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed10514    
    Printed222    
    Emailed9    
    PDF Downloaded398    
    Comments [Add]    
    Cited by others 6    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2009  |  Volume : 57  |  Issue : 3  |  Page : 300--303

The efficacy and safety of gabapentin in carpal tunnel patients: Open label trial


Ayhan Varlibas, Kirikkale University, Faculty of Medicine, Department of Neurology, Kirikkale, 07100, Turkey

Correspondence Address:
A Kemal Erdemoglu
Kirikkale University, Faculty of Medicine, Department of Neurology, Kirikkale, 07100
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.53287

Rights and Permissions

Background: Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy caused by median nerve compression at the wrist. It results in loss of considerable man days and the effectiveness the various treatment modalities are still debated. Aim: To study the efficacy of gabapentin in patients with CTS. The study aim is to investigate the efficacy of gabapentin in patients with CTS patients who were refractory to the other conservative measures or unwilling for the surgical procedure. Materials and Methods: Forty one patients diagnosed as idiopathic CTS were included in the study. Patients were assessed with symptom severity scale (SSS) and functional status scale (FSS) scores of Boston Carpal Tunnel Questionnaire (BCTQ) before and at 1, 3, and 6 months of the treatment. Response to therapy was determined by using SSS and FSS scores of BCTQ. Results: The median dosage of gabapentin was 1800 mg/daily. Side effects were mild and transient. There was a statistically significant difference in both symptom SSS and FSS scores between before and after treatment in patient groups at the end of six months (P < 0.001). According to grading the changes in subscales of BCTQ, of 41 patients, 34.1 and 29.3 had a ≥ 40% decrease in SSS and FSS, respectively. Conclusion: Gabapentin was found to be partially effective and safe in symptomatic treatment of CTS patients.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow